BioWorld Asia

Sep. 15, 2010

Roche, reMYND in Pact to Develop PD, AD Drugs

Roche AG and reMYND will join forces to develop two classes of compounds against Parkinson's disease and Alzheimer's disease. The total deal is worth as much as $637 million to reMYND as milestones are met. (BioWorld International) Read More

Acceleron, Shire Partner in $498M Orphan Disease Deal

Transgene Stock Rises on Jennerex Oncolytic Virus Deal

Ark Rebuilds Post-Cerepro Failure, Headcount Cut

Abiraterone Improves Survival in Prostate Cancer Phase III

Pharming Closes $20M Deal for Rhucin with Santarus

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Atai Therapeutics patents new 5-HT2 receptor agonists

BioWorld Science

Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.